RedHill Biopharma (RDHL) EBT (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of EBT data on file, last reported at $58.9 million in Q2 2023.

• On a quarterly basis, EBT rose 791.8% year-over-year to $58.9 million in Q2 2023; TTM through Jun 2023 was -$40.0 million, a 60.47% increase from a year earlier, with the FY2025 full-year figure at -$429000.0, up 94.81% from the prior year.
• EBT for Q2 2023 stood at $58.9 million, up from -$7.9 million in the prior quarter.
• Over the last five years, EBT for RDHL reached as high as $58.9 million in Q2 2023 and fell as low as -$134.0 million in Q4 2021.
• Historically, EBT has averaged -$271388.9 across 5 years, with a median of $11.1 million in 2019.
• Across the five-year window, EBT sank 714.12% in 2021 and surged 791.8% in 2023, its largest moves.
• Year by year, EBT stood at $11.8 million in 2019, then soared by 84.27% to $21.8 million in 2020, then sank by 714.12% to -$134.0 million in 2021, then surged by 48.1% to -$69.5 million in 2022, then surged by 184.75% to $58.9 million in 2023.
• Per Business Quant data, the three most recent EBT figures were $58.9 million in Q2 2023, -$7.9 million in Q1 2023, and -$69.5 million in Q4 2022.